Canada Life’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-6,242
| Closed | -$297K | – | 1871 |
|
|
2025
Q3 | $297K | Hold |
6,242
| – | – | ﹤0.01% | 1662 |
|
|
2025
Q2 | $334K | Buy |
6,242
+2,192
| +54% | +$99.6K | ﹤0.01% | 1664 |
|
|
2025
Q1 | $164K | Hold |
4,050
| – | – | ﹤0.01% | 1735 |
|
|
2024
Q4 | $112K | Hold |
4,050
| – | – | ﹤0.01% | 1799 |
|
|
2024
Q3 | $116K | Hold |
4,050
| – | – | ﹤0.01% | 1840 |
|
|
2024
Q2 | $95K | Hold |
4,050
| – | – | ﹤0.01% | 1888 |
|
|
2024
Q1 | $102K | Hold |
4,050
| – | – | ﹤0.01% | 1922 |
|
|
2023
Q4 | $94K | Hold |
4,050
| – | – | ﹤0.01% | 1957 |
|
|
2023
Q3 | $205K | Buy |
4,050
+2,564
| +173% | +$119K | ﹤0.01% | 1851 |
|
|
2023
Q2 | $70K | Hold |
1,486
| – | – | ﹤0.01% | 1966 |
|
|
2023
Q1 | $57K | Hold |
1,486
| – | – | ﹤0.01% | 2046 |
|
|
2022
Q4 | $82K | Buy |
1,486
+901
| +154% | +$38.6K | ﹤0.01% | 2013 |
|
|
2022
Q3 | $20K | Hold |
585
| – | – | ﹤0.01% | 2259 |
|
|
2022
Q2 | $6K | Hold |
585
| – | – | ﹤0.01% | 2404 |
|
|
2022
Q1 | $9K | Hold |
585
| – | – | ﹤0.01% | 2438 |
|
|
2021
Q4 | $12K | Hold |
585
| – | – | ﹤0.01% | 2432 |
|
|
2021
Q3 | $13K | Hold |
585
| – | – | ﹤0.01% | 2485 |
|
|
2021
Q2 | $15K | Sell |
585
-903
| -61% | -$25.4K | ﹤0.01% | 2519 |
|
|
2021
Q1 | $43K | Hold |
1,488
| – | – | ﹤0.01% | 2333 |
|
|
2020
Q4 | $38K | Hold |
1,488
| – | – | ﹤0.01% | 2375 |
|
|
2020
Q3 | $46K | Hold |
1,488
| – | – | ﹤0.01% | 2199 |
|
|
2020
Q2 | $37K | Buy |
+1,488
| New | +$34K | ﹤0.01% | 2320 |
|
Other funds holding AKRO
Canada Life's AKRO Position: Q4 2025 in Review
Canada Life sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 6,242 shares — an estimated $297K sold.
Canada Life first reported a position in AKRO in Q2 2020 and held it in 22 quarters. The position peaked at $334K in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.
- Canada Life reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
- Canada Life sold 6,242 Akero Therapeutics shares in Q4 2025, an estimated $297K.
- Canada Life first reported a position in Akero Therapeutics in Q2 2020 and held it in 22 quarters.
- Canada Life's Akero Therapeutics position peaked at $334K in Q2 2025.
- 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.
Based on Canada Life's 13F filing for Q4 2025, filed 13 Feb 2026.